Supported by strong evidence in developmental, evolutionary and cancer biology, we hypothesize that K-RAS/SIAH pathway activation is a major tumor driver, and SIAH represents a strategically well-positioned tumor vulnerability and a new therapeutic target against chemo-resistant, relapsed, and metastatic TNBC in the future (Figure 1A). This evidence concerns the gene KRAS and neoplasm.